Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Daxor
(NASDAQ:DXR)
Intraday
$9.65
0
[0.00%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$9.65
0
[0.00%]
Last update: 10:06AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Daxor Stock (NASDAQ:DXR)
Daxor Stock (NASDAQ: DXR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, March 25, 2024
Daxor Corporation Acquires Volumex And Megatope From Its Existing Supplier Along With Glofil To Enhance Existing Suite Of Diagnostics; No Financial Terms Disclosed
Benzinga Newsdesk
-
Mar 25, 2024, 8:11AM
Monday, March 18, 2024
Daxor Announces As Of December 31, 2023, Daxor's Net Assets Were $34,010,384 Or $7.08 Per Share, Revenue Increased 31.8% Year On Year For 2023 Versus 2022, Provides Corporate Update In Letter To Shareholders
Benzinga Newsdesk
-
Mar 18, 2024, 3:09PM
Monday, March 11, 2024
Daxor Announces Sales To Three New Hospitals Furthering Expansion Of Its User Base
Benzinga Newsdesk
-
Mar 11, 2024, 8:10AM
Monday, February 12, 2024
Daxor Announces Two Significant New Customer Transactions With The Co's BVA-100 In January; No Financial Terms Disclosed
Benzinga Newsdesk
-
Feb 12, 2024, 8:15AM
Wednesday, February 07, 2024
Daxor Corporation Closes Q4 2023 With Growth In New Sales To Hospital Systems And Increased Utilization Of Its BVA-100 Blood Volume Diagnostic Across The U.S. At Existing Accounts
Benzinga Newsdesk
-
Feb 7, 2024, 8:06AM
Tuesday, January 09, 2024
Daxor Announces That The United States Patent And Trademark Office Has Issued The Company A Second Patent, Safeguarding A Distinctive Clinical Guidance System For Blood Volume Management
Benzinga Newsdesk
-
Jan 9, 2024, 8:04AM
Tuesday, January 02, 2024
Daxor Announces It Has Submitted Its Blood Volume Analyzer, Daxor BVA, To The FDA
Benzinga Newsdesk
-
Jan 2, 2024, 8:33AM
Monday, November 13, 2023
Daxor Corporation Announces Presentation Of Data From Phase I NIH-Sponsored Trial At American Heart Association Annual Meeting
Benzinga Newsdesk
-
Nov 13, 2023, 8:03AM
Thursday, November 09, 2023
Daxor Corporation Awarded New Patent For Remote Monitoring Of Blood Volume
Benzinga Newsdesk
-
Nov 9, 2023, 8:20AM
Friday, November 03, 2023
Chief Financial Officer at Daxor Acquires Company Stock Options Worth 5,000 Shares
Benzinga Insights
-
Nov 3, 2023, 11:00AM
Wednesday, October 11, 2023
Daxor Corp Announces New Data From Banner University Medicine Demonstrating Effectiveness Of BVA-100 Use In Ambulatory Heart Failure Patients Presented At Heart Failure Society Of America Annual Scientific Meeting
Benzinga Newsdesk
-
Oct 11, 2023, 8:04AM
Wednesday, October 04, 2023
Daxor Corp Wins Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program
Benzinga Newsdesk
-
Oct 4, 2023, 8:04AM
Monday, September 11, 2023
Daxor Corporation Awarded $305K Grant From The National Institutes Of Health To Develop Blood Volume Guidance Software In Sepsis Patients
Benzinga Newsdesk
-
Sep 11, 2023, 12:02PM
Thursday, August 10, 2023
Daxor Corporation Announces Publication Of Research Letter Of Heart Failure Trial With Daxor BVA-100
Benzinga Newsdesk
-
Aug 10, 2023, 8:03AM
Friday, July 14, 2023
Daxor Director Awarded $24K Worth of Stock Options
Benzinga Insights
-
Jul 14, 2023, 11:02AM
Daxor Chairman Awarded $298K Worth of Stock Options
Benzinga Insights
-
Jul 14, 2023, 11:02AM
Chief Scientific Officer at Daxor Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights
-
Jul 14, 2023, 11:02AM
Board Member at Daxor Acquires Company Stock Options Worth 2,500 Shares
Benzinga Insights
-
Jul 14, 2023, 11:01AM
Director at Daxor Acquires Company Stock Options Worth 2,500 Shares
Benzinga Insights
-
Jul 14, 2023, 11:01AM
Chief Financial Officer at Daxor Acquires Company Stock Options Worth 14,000 Shares
Benzinga Insights
-
Jul 14, 2023, 11:01AM
Tuesday, July 11, 2023
Daxor Corporation Announces Further Acquisitions And Increased Utilization Of Its BVA-100 Blood Volume Diagnostic Throughout The U.S.
Happy Mohamed
-
Jul 11, 2023, 8:26AM
Wednesday, July 05, 2023
Daxor Corporation Awarded $1.1M Contract From The U.S. Defense Health Agency For Added Capabilities To Its Point-Of-Care Blood Volume Analyzer
Happy Mohamed
-
Jul 5, 2023, 8:07AM
Monday, May 22, 2023
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
May 22, 2023, 1:20PM
Daxor Corporation Announces Pricing Of $4M Underwritten Public Offering Of 410,260 Shares Of Its Common Stock At A Price Of $9.75/Share
Benzinga Newsdesk
-
May 22, 2023, 8:34AM
Daxor shares are trading lower after the company announced a proposed underwritten public offering.
Benzinga Newsdesk
-
May 22, 2023, 8:21AM
Why Immix Biopharma Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
May 22, 2023, 8:06AM
Thursday, May 18, 2023
New Study Demonstrates Clinical Utility Of Daxor's Blood Volume Diagnostic In Heart Failure Outcomes
Happy Mohamed
-
May 18, 2023, 8:22AM
Monday, March 27, 2023
Daxor Announces Five New Hospitals Have Implemented Its BVA-100 Blood Volume Diagnostic For Clinical Use To Guide Fluid Management In Heart Failure Patients During The First Quarter Of 2023.
Benzinga Newsdesk
-
Mar 27, 2023, 8:09AM
Thursday, March 23, 2023
New Study Confirms Daxor's BVA-100 Volume Metric Compared To CardioMEMS Pressure Metric Has Unique Clinical Utility As A Diagnostic For Heart Failure Patients
Happy Mohamed
-
Mar 23, 2023, 8:42AM
Tuesday, November 15, 2022
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Nov 15, 2022, 12:32PM
Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected
Lisa Levin
-
Nov 15, 2022, 10:12AM
Daxor shares are trading lower after the company announced pricing of a $2 million underwritten public offering.
Benzinga Newsdesk
-
Nov 15, 2022, 9:24AM
Daxor Corporation Announces Pricing of $2M Underwritten Public Offering
Benzinga Newsdesk
-
Nov 15, 2022, 8:46AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Nov 15, 2022, 8:31AM
Monday, November 14, 2022
Daxor Corporation Announces Launch of Proposed Underwritten Public Offering; No Terms Disclosed
Benzinga Newsdesk
-
Nov 14, 2022, 5:07PM
Thursday, November 03, 2022
Newly Published Study Demonstrates Significant Clinical Utility Of Daxor's Blood Volume Diagnostic In The Evaluation Of Heart Failure
Benzinga Newsdesk
-
Nov 3, 2022, 8:26AM
Tuesday, October 04, 2022
Study Data From Mayo Clinic On Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented At Key Scientific Meeting On October 2nd; More Than 50% Discharged From Hospital With Suboptimal Treatment
Benzinga Newsdesk
-
Oct 4, 2022, 8:04AM
Monday, October 03, 2022
New Studies Validating The Uniqueness Of The BVA-100 Blood Test For Heart Failure Patients Compared To Pressure Measures; Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care
Benzinga Newsdesk
-
Oct 3, 2022, 8:46AM
Thursday, July 21, 2022
Daxor Corporation Announces Partnership With Medaxiom To Advance Awareness And Further Adoption Of Daxor's Blood Volume Diagnostic (BVA-100)
Bill Haddad
-
Jul 21, 2022, 8:11AM
Monday, June 27, 2022
Daxor Announces Cooperative Research And Development Phase II Agreement With The Uniformed Armed Services University For The Development Of A Non-nuclear Blood Volume Analysis Device
Benzinga Newsdesk
-
Jun 27, 2022, 8:10AM
Wednesday, May 25, 2022
Daxor Reports Will Participate In National Institutes Of Health Intramural Research Program-Sponsored Study For COVID Utilizing Co.'s Blood Volume Analyzer, No Terms Disclosed
Benzinga Newsdesk
-
May 25, 2022, 8:02AM
Monday, May 02, 2022
Daxor Highlights New Data Validating Benefits Of Co.'s BVA-100 Blood Test For Advanced Heart Failure Patients
Benzinga Newsdesk
-
May 2, 2022, 8:18AM
Tuesday, March 01, 2022
Daxor Reports FY21 EPS $5.24
Benzinga Newsdesk
-
Mar 1, 2022, 8:05AM
Thursday, February 17, 2022
Daxor Reports Study Showed Importance, Clinical Utility Of Co.'s Blood Volume Diagnostic For Assessment Of Heart Failure
Benzinga Newsdesk
-
Feb 17, 2022, 8:06AM
Wednesday, January 05, 2022
Daxor Announces Completion Of Patient Enrollment In Multicenter BVA-100 Study In Hospitalized Patients With COVID-19
Bill Haddad
-
Jan 5, 2022, 8:02AM
Tuesday, January 04, 2022
Daxor Awarded U.S. Patent For Blood Volume Guidance Technology To Improve Treatment And Outcomes
Benzinga Newsdesk
-
Jan 4, 2022, 8:11AM
Tuesday, November 16, 2021
Daxor Corporation Presents New Data Validating The Benefit Of The BVA-100 Blood Test For Optimal Heart Failure Management At Key Scientific Society Meeting
Benzinga Newsdesk
-
Nov 16, 2021, 8:15AM
Tuesday, September 14, 2021
Daxor Highlights Presentation Of BVA-100 Blood Test Data At Heart Failure Society of America Annual Scientific Meeting 2021
Bill Haddad
-
Sep 14, 2021, 8:34AM
Wednesday, September 08, 2021
Daxor Corporation To Present New Data, Clinical Trials Utilizing BVA-100 Blood Test At Heart Failure Society Of America Annual Scientific Meeting 2021
Benzinga Newsdesk
-
Sep 8, 2021, 8:50AM
Wednesday, September 01, 2021
Daxor Corporation CEO And President Michael Feldschuh Provides Corporate Update In Letter To Shareholders
Bill Haddad
-
Sep 1, 2021, 8:33AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch